R. Obrist

861 total citations
47 papers, 610 citations indexed

About

R. Obrist is a scholar working on Oncology, Immunology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, R. Obrist has authored 47 papers receiving a total of 610 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Oncology, 13 papers in Immunology and 11 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in R. Obrist's work include Monoclonal and Polyclonal Antibodies Research (11 papers), Toxin Mechanisms and Immunotoxins (6 papers) and Glycosylation and Glycoproteins Research (5 papers). R. Obrist is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (11 papers), Toxin Mechanisms and Immunotoxins (6 papers) and Glycosylation and Glycoproteins Research (5 papers). R. Obrist collaborates with scholars based in Switzerland, United States and Belgium. R. Obrist's co-authors include J.P. Obrecht, Christian Ludwig, R. Landmann, Robert C. Bast, Antonio Lanzavecchia, Doris Scheidegger, Sergio Abrignani, Bernd Dörken, G Moldenhauer and Patrick Petignat and has published in prestigious journals such as The Journal of Experimental Medicine, Biochemical and Biophysical Research Communications and American Journal of Obstetrics and Gynecology.

In The Last Decade

R. Obrist

46 papers receiving 571 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
R. Obrist Switzerland 14 237 141 138 103 89 47 610
Hiroyuki Furumoto Japan 15 199 0.8× 181 1.3× 258 1.9× 48 0.5× 169 1.9× 42 752
G Hamilton Canada 12 233 1.0× 234 1.7× 234 1.7× 28 0.3× 73 0.8× 28 850
Ivan Kehayov Bulgaria 12 189 0.8× 61 0.4× 200 1.4× 42 0.4× 136 1.5× 32 627
V. Barak Israel 13 218 0.9× 88 0.6× 206 1.5× 20 0.2× 204 2.3× 28 774
Judith Leibovici Israel 15 196 0.8× 238 1.7× 318 2.3× 28 0.3× 16 0.2× 83 698
M Ohkubo Japan 9 142 0.6× 86 0.6× 311 2.3× 22 0.2× 22 0.2× 16 650
Philip C. Kelleher United States 14 56 0.2× 92 0.7× 303 2.2× 55 0.5× 35 0.4× 34 660
Xi Xia China 22 152 0.6× 129 0.9× 517 3.7× 34 0.3× 198 2.2× 53 1.1k
Nianyu Li United States 15 773 3.3× 457 3.2× 248 1.8× 65 0.6× 80 0.9× 24 1.2k
Guirong Sun China 14 61 0.3× 131 0.9× 182 1.3× 35 0.3× 42 0.5× 32 587

Countries citing papers authored by R. Obrist

Since Specialization
Citations

This map shows the geographic impact of R. Obrist's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Obrist with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Obrist more than expected).

Fields of papers citing papers by R. Obrist

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. Obrist. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Obrist. The network helps show where R. Obrist may publish in the future.

Co-authorship network of co-authors of R. Obrist

This figure shows the co-authorship network connecting the top 25 collaborators of R. Obrist. A scholar is included among the top collaborators of R. Obrist based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. Obrist. R. Obrist is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zwahlen, Marcel, Nicola Low, Bettina Borisch, et al.. (2010). Population-based screening – the difficulty of how to do more good than harm and how to achieve it. Swiss Medical Weekly. 140(3738). w13061–w13061. 11 indexed citations
2.
Obrist, R., et al.. (2008). Tumorpatient und Paramedizin: Versuch einer Charakterisierung von Anwendern unkonventioneller Therapieverfahren in der Onkologie*. DMW - Deutsche Medizinische Wochenschrift. 114(9). 323–330. 1 indexed citations
3.
Petignat, Patrick, D. de Weck, Frédéric Goffin, et al.. (2006). Long-Term Survival of Patients with Apparent Early-Stage (FIGO I–II) Epithelial Ovarian Cancer: A Population-Based Study. Gynecologic and Obstetric Investigation. 63(3). 132–136. 6 indexed citations
4.
Petignat, Patrick, et al.. (2000). Surgical management of epithelial ovarian cancer at community hospitals: A population-based study. Journal of Surgical Oncology. 75(1). 19–23. 14 indexed citations
5.
Obrist, R.. (1994). Aggressive non-Hodgkin's lymphoma in elderly patients: Where to go from here?. European Journal of Cancer. 30(9). 1213–1214. 3 indexed citations
6.
Obrist, R., H. Denz, Christian Ludwig, et al.. (1993). Pharmacokinetics and immunomodulatory effects on monocytes during prolonged therapy with liposomal muramyltripeptide. Biotherapy. 7(1). 1–12. 15 indexed citations
7.
8.
Landmann, R., Christian Ludwig, M. Wesp, et al.. (1992). Prolonged Interferon-γ Application by Subcutaneous Infusion in Cancer Patients: Differential Response of Serum CD14, Neopterin, and Monocyte HLA Class I and II Antigens. Journal of Interferon Research. 12(2). 103–111. 11 indexed citations
9.
Obrist, R., et al.. (1991). Acute and subacute toxicity of chemotactic conjugates between monoclonal antibody and fMet-Leu-Phe in humans: A phase I clinical trial. Cancer Immunology Immunotherapy. 32(6). 406–408. 4 indexed citations
10.
Landmann, R., Christian Ludwig, R. Obrist, & J.P. Obrecht. (1991). Effect of cytokines and lipopolysaccharide on CD14 antigen expression in human monocytes and macrophages. Journal of Cellular Biochemistry. 47(4). 317–329. 66 indexed citations
11.
Obrist, R., et al.. (1990). Prostatakarzinom mit einer ungewöhnlichen Verlaufsform. Oncology Research and Treatment. 13(5). 388–391. 4 indexed citations
12.
Borner, Markus, U Laffer, R. Obrist, et al.. (1990). Effectiveness and low toxicity of hepatic artery infusion with fluorouracil and mitomycin for metastatic colorectal cancer confined to the liver. Annals of Oncology. 1(3). 227–228. 7 indexed citations
13.
Landmann, R., et al.. (1990). Recombinant interferon γ up-regulates in vivo and down-regulates in vitro monocyte CD14 antigen expression in cancer patients. Cancer Immunology Immunotherapy. 31(5). 292–296. 13 indexed citations
14.
Obrist, R., et al.. (1990). Improved Tolerance of Interferon alpha-2a by Continuous Subcutaneous Infusion. Oncology Research and Treatment. 13(2). 117–122. 4 indexed citations
15.
Obrist, R.. (1989). [Who uses alternative therapy in cancer? A patient survey].. PubMed. 78(41). 1119–20. 1 indexed citations
16.
Obrist, R., et al.. (1989). Selection of highly malignant tumour cells using reconstituted basement membrane matrix.. PubMed. 9(1). 15–26. 3 indexed citations
17.
Obrist, R., et al.. (1988). Chemotactic monoclonal antibody conjugates: A comparison of four different f — MET — peptide — conjugates. Biochemical and Biophysical Research Communications. 155(3). 1139–1144. 1 indexed citations
18.
Berek, Jonathan S., Robert C. Knapp, Neville F. Hacker, et al.. (1985). Intraperitoneal immunotherapy of epithelial ovarian carcinoma with Corynebacterium parvum. American Journal of Obstetrics and Gynecology. 152(8). 1003–1010. 29 indexed citations
19.
Bast, Robert C., Jonathan S. Berek, R. Obrist, et al.. (1983). Intraperitoneal immunotherapy of human ovarian carcinoma with Corynebacterium parvum.. PubMed. 43(3). 1395–401. 51 indexed citations
20.
Obrist, R., et al.. (1978). Identification of lymphocyte subpopulations by simultaneous E-rosette formation and unspecific acid esterase staining. Cellular and Molecular Life Sciences. 34(5). 660–661. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hiroyuki Furumoto Breakdown of academic impact, for papers by G Hamilton Breakdown of academic impact, for papers by Ivan Kehayov Breakdown of academic impact, for papers by V. Barak Breakdown of academic impact, for papers by Judith Leibovici Breakdown of academic impact, for papers by M Ohkubo Breakdown of academic impact, for papers by Philip C. Kelleher Breakdown of academic impact, for papers by Xi Xia Breakdown of academic impact, for papers by Nianyu Li Breakdown of academic impact, for papers by Guirong Sun
Rankless by CCL
2026